

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Trends in Immunology

Forum

Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern

Shan Su,¹ Weihua Li,² and Shibo Jiang ^{1,2,*}

The concurrent prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East respiratory syndrome coronavirus (MERS-CoV) raises the concern for the emergence of potential new β-CoV clades via genetic recombination, bearing high SARS-CoV-2-like transmissibility and high MERS-CoV-like mortality rates. Therefore, we argue that there is an urgent need to develop pan-B-CoV vaccines that can target not only current SARS-CoV-2 variants of concern, but also future putative SARS-CoV-3- or MERS-CoV-2-like coronavirus.

The development of effective vaccines was considered by some as potentially bringing a quick end to the economic and social ravages of the coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2. However, since the end of 2020, many SARS-CoV-2 variants of concern (VOCs), such as the Beta and Delta variants, have emerged. These VOCs have shown neutralization resistance to post-vaccination sera in humans and animal models and raised concerns over the apparent waning of protective immunity for the first-generation COVID-19 vaccines that were authorized for emergency use. This cast a shadow over previous expectations. A recent study showed that

vaccine efficacy against infections of the Delta variant declined from 93% to 53% at only 4 months post-vaccination in humans [1]. Moreover, SARS-CoV-2 is feared to further mutate into escape variants under the selection pressure of antibodies in COVID-19 convalescents and vaccinees, such as the VOC Omicron (B.1.1.529), which harbors 32 mutations in the Spike protein, the latest SARS-CoV-2 VOC that was first reported to the World Health Organization (WHO) from South Africa on 24 November 2021 [2]. Many groups are investigating this rapid mutagenesis phenomenon by analyzing the impact of such mutants on viral entry and replication and neutralization by antibody or vaccine-induced immune responses, as well as cellular and tissue tropism. It is not hard to envision a case where SARS-CoV-2 or MERS-CoV may further evolve into a new clade, SARS-CoV-3 or MERS-CoV-2, respectively, by genetic recombination between SARS-CoV-2 and MERS-CoV. We know that SARS-CoV-2 and MERS-CoV are concurrently prevalent in the Arabian Peninsula and that genetic recombination can occur on the infection and replication of both SARS-CoV-2 and MERS-CoV in the same host, given that both viruses can infect the same cell (type-II alveolar) and they use identical transcription regulatory sequences, conserved sequences upstream of open reading frames that can mediate discontinuous transcription of the viral genome [3,4]. Moreover, the receptorbinding domain (RBD) of SARS-CoV-2 can putatively bind to dipeptidylpeptidase (DPP4), the MERS-CoV receptor, 4 based on bioinformatics analysis combining human-virus protein interaction prediction and protein docking [5]. Several cases of SARS-CoV-2 and MERS-CoV co-infection have been reported in Saudi Arabia [6], with a foreboding possibility of recombination between these two viruses.

Historically, SARS-CoV-2 was thus named based on phylogenetic analysis, which

suggests that it forms a sister clade with human SARS-CoV and bat SARSrelated coronavirus (SARSr-CoV) prototypes (Figure 1) [7]. Following this logic, a novel SARS-CoV-3 could emerge if SARS-CoV-2 obtains a genomic segment from MERS-CoV. In addition, presumably, SARS-CoV-3 might preserve the high transmissibility potential of SARS-CoV-2 but acquire the high case-fatality rate (CFR) (35%) of MERS-CoV, whereas the global CFR of SARS-CoV-2 is about 2% based on the information reported by the WHO (https:// covid19.who.int/). Similarly, a MERS-CoV-2 might preserve the high CFR of MERS-CoV, while potentially gaining the higher transmissibility rate of SARS-CoV-2. Such a hypothesis calls for the urgent development of pan-B-CoV vaccines that could combat any possible development of future SARS-CoV-3 or MERS-CoV-2.

Currently, many research groups are working on the development of CoV vaccines that are cross-reactive to sarbecovirus, lineage B of the Betacoronavirus genus (primary-level breadth), including SARS-CoV, SARS-CoV-2, and SARSr-CoVs. One study, for example, reported that mosaic nanoparticles comprising the RBDs of four to eight distinct zoonotic coronaviruses, including SARS-CoV, SARS-CoV-2, and some SARSr-CoVs from bats, elicited cross-reactive immune responses against these coronaviruses in mice [8]. Although the RBD of coronaviruses mutates frequently, recent work from our laboratory showed that the neutralizing antibodies (NAbs) induced by SARS-CoV-2 RBD linked to a human IgG Fc fragment (RBD-Fc) crossneutralized infection by sarbecoviruses, including SARS-CoV, SARS-CoV-2, and some SARSr-CoVs from bats, in mice [9]. Moreover, another group demonstrated that the immunization of macaques with SARS-CoV-2 RBD-conjugated nanoparticles elicited cross-NAb responses against bat coronaviruses, SARS-CoV, and SARS-CoV-2 [10]. In addition, another




Figure 1. Phylogenetic tree of coronaviruses. Viruses in *Coronaviridae* are divided into four genera: Alphacoronavirus (α -CoV), Betacoronavirus (β -CoV), Gammacoronavirus (γ -CoV), and Deltacoronavirus (δ -CoV). Sarbecovirus is the B lineage of the β -CoV that might emerge in the near future by genetic recombination and could hypothetically be termed severe acute respiratory syndrome coronavirus 3 (SARS-CoV-3) or Middle East respiratory syndrome coronavirus 2 (MERS-CoV-2).

study reported the development of a SARS-CoV-2 Spike protein ferritin nanoparticle (SpFN) vaccine, formulated with a liposomal adjuvant, that induced highly potent and broad NAb responses against the SARS-CoV-2 variants and SARS-CoV in nonhuman primates [11]. This SpFN vaccine entered a Phase I clinical trial in March 2021 (NCT04784767)¹. Furthermore, others have documented the presence of potent cross-clade pan-sarbecovirus NAbs in the sera of SARS-CoV survivors immunized with an mRNA (BNT162b2) vaccine [12], indicating that sequential administration of SARS-CoV and SARS-CoV-2 vaccines might be a putative approach to achieving a pan-sarbecovirus

vaccine – a possibility that will require robust assessment.

Trends in Immunology

According to the protection range of a certain vaccine, we divided the coronavirus vaccines into three levels (Figure 1). The vaccines that can protect against infection with all sarbecoviruses, all Betacoronaviruses, and all coronaviruses fall into primarylevel, middle-level, and high-level breadth, respectively. We argue that these efforts can result in successful pan-sarbecovirus (primary-level breadth) vaccines. However, as hypothesized in the preceding text, a pan- β -CoV vaccine (middle-level breadth) is urgently needed to curtail the potential pandemic tide of a likely SARS- CoV-3 or MERS-CoV-2. Of note, SARS-CoV-2-reactive CD4⁺ T cells have been detected in the blood of around 35% of unexposed healthy individuals; moreover, in vitro analyses have shown that the numbers of activated CD4⁺ T cells increase after the incubation of isolated SARS-CoV-2-specific CD4⁺ T cells with peptides derived from the Spike proteins of human endemic coronavirus 229E (belongs to α-CoV; Figure 1) and OC43 (belongs to β -CoV), indicating that SARS-CoV2-specific CD4⁺ T could also respond to coronaviruses from other genera [13]. This study suggests the presence of cross-reactive CD4⁺ T cells that might be induced by other coronaviruses in human blood. However, this does not mean that pan-coronavirus vaccine (high-level breadth) could become available based on the induction of cross-reactive CD4⁺ T cells.

First, rare evidence suggests that T cell responses can correlate with protection; however, many studies have shown that NAb titers induced by vaccines positively correlate with protection against symptomatic and asymptomatic SARS-CoV-2 infection in vaccinated subjects [14]. Second, T cell immune-based pan-CoV vaccines with low neutralization immunogenicity may induce a suboptimal concentration of NAbs that may enhance SARS-CoV-2 infection by antibody-dependent enhancement (ADE) of viral entry [15], despite the fact that researchers have reported findings in which non-NAbs that show ADE in vitro can still protect against SARS-CoV-2 replication in monkeys and mice [16]. Therefore, while chasing pan-β-CoV vaccines, taking into account both the titer of NAbs and the T cell responses induced by vaccines will be an important measure for efficacy and safety, moving forward.

We posit that it may be more realistic to develop a middle-level-breadth vaccine (i.e., pan- β -CoV vaccine) than a high-level vaccine (i.e., pan-CoV vaccine against



CellPress

Trends in Immunology

the currently circulating SARS-CoV-2 and MERS-CoV as well as their variants and possible related new clades; e.g., SARS-CoV-3, MERS-CoV-2) to be able to equip ourselves for the possible emerging SARS-CoV-2 VOCs and SARS-CoV-3 or MERS-CoV-2 outbreaks.

Acknowledgments

The authors gratefully acknowledge funding received from the National Natural Science of China (82041025).

Author contributions

Conceptualization and funding: S.J. Writing – original draft: S.S. Writing – review and editing: S.J. and W.L.

Declaration of interests

The authors declare no interests.

Resources

ⁱhttps://clinicaltrials.gov/ct2/show/NCT04784767

¹Key Laboratory of Medical Molecular Virology (MOE/MOH/ CAM), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai 200032, China ²NHC Key Lab of Reproduction Regulation (Shanghai Institute for Biomedical and Pharmaceutical Technologies), Fudan University, Shanghai 200032, China

*Correspondence: shibojiang@fudan.edu.cn (S. Jiang). https://doi.org/10.1016/j.it.2022.01.009

© 2022 Elsevier Ltd. All rights reserved.

References

- Tartof, S.Y. et al. (2021) Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet* 398, 1407–1416
- World Health Organization (2021) Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern. Published online November 26, 2021. https://www.who.int/news/ item/26-11-2021-classification-of-omicron-(b.1.1.529)sars-cov-2-variant-of-concern
- Van Boheemen, S. et al. (2012) Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 3, e00473-12
- Wu, F. et al. (2020) A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269
- Li, Y. et al. (2020) The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 Spike. *iScience* 23, 101400
- Elhazmi, A. *et al.* (2021) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East respiratory syndrome coronavirus (MERS-CoV) coinfection: a unique case series. *Travel Med. Infect. Dis.* 41, 102026

- Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (2020) The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544
- Cohen, A.A. *et al.* (2021) Mosaic nanoparticles elicit crossreactive immune responses to zoonotic coronaviruses in mice. *Science* 371, 735–741
- Liu, Z. et al. (2020) RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal. Transduct. Target Ther. 5, 282
- Saunders, K.O. *et al.* (2021) Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. *Nature* 594, 553–559
- Joyce, M.G. et al. (2021) Efficacy of a broadly neutralizing SARS-CoV-2 ferritin nanoparticle vaccine in nonhuman primates. *bioRxiv* Published online March 25, 2021. https://doi.org/10.1101/2021.03.24.436523
- Tan, C.W. et al. (2021) Pan-sarbecovirus neutralizing antibodies in BNT162b2-immunized SARS-CoV-1 survivors. *N. Engl. J. Med.* 385, 1401–1406
- Braun, J. *et al.* (2020) SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. *Nature* 587, 270–274
- Feng, S. et al. (2021) Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat. Med.* 27, 2032–2040
- Su, S. et al. (2021) Learning from the past: development of safe and effective COVID-19 vaccines. Nat. Rev. Microbiol. 19, 211–219
- Li, D. et al. (2021) In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell 184, 4203–4219.e4232